Scott Kopetz, MD, PhD, FACP

Dr Kopetz discusses the value of ctDNA assays, trials that have shown prognostic implications with this type of assay, and the future of ctDNA research.

Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, discuss how ctDNA assays have improved MRD detection in CRC.

Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, discuss ongoing research in CRC utilizing ctDNA.

Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, discuss how to approach conversations about ctDNA with patients with CRC.

Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, discuss findings for ctDNA in stage II/III CRC from the BESPOKE CRC trial.

Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, on data from the GALAXY arm of CIRCULATE-Japan for ctDNA in stage II to IV CRC.

Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, on why ctDNA remains a focus of research in colorectal cancer.

Scott Kopetz, MD, PhD, FACP, discusses the safety of encorafenib plus cetuximab with/without chemotherapy in BRAF V600E–mutant metastatic colorectal cancer.

Scott Kopetz, MD, PhD, FACP, discusses findings from the phase 3 BREAKWATER study of frontline encorafenib plus cetuximab with or without chemotherapy in BRAF V600E–mutated metastatic CRC.

Scott Kopetz, MD, PhD, FACP, discusses the potential FDA approval of adagrasib in combination with cetuximab in KRAS G12C-mutatated colorectal cancer.

Scott Kopetz, MD, PhD, FACP, discusses using adagrasib plus cetuximab in patients with metastatic colorectal cancer harboring KRAS G12C mutations.

Scott Kopetz, MD, PhD, FACP, discusses the clinical efficacy and safety of adagrasib plus cetuximab in patients with KRAS G12C-mutated mCRC.

Scott Kopetz, MD, PhD, FACP, discusses the phase 3 BREAKWATER trial in patients with BRAF V600E–mutant metastatic colorectal cancer.

Scott Kopetz, MD, PhD, FACP, discusses the rationale for launching the phase 3 BREAKWATER trial in BRAF V600E­–mutant metastatic colorectal cancer.

Scott Kopetz, MD, PhD, FACP, discusses the safety lead-in data from the phase 3 BREAKWATER trial in patients with BRBRAF V600E–mutant metastatic colorectal cancer.

Scott Kopetz, MD, PhD, FACP, discusses the phase 3 BEACON CRC study and the subsequent efficacy response analysis in patients with BRAF V600E–mutant metastatic colorectal cancer.

Edmund Scott Kopetz, MD, PhD, FACP, discusses the utilization of circulating tumor DNA in colorectal cancer.

Edmund Scott Kopetz, MD, PhD, FACP, discusses the current state of circulating tumor DNA testing in colorectal cancer.

Edmund Scott Kopetz, MD, PhD, FACP, discusses the rationale for the ongoing phase 3 BREAKWATER trial in BRAF V600E-mutant metastatic colorectal cancer.

Scott Kopetz, MD, PhD, FACP, discusses the design of the phase 3 BEACON CRC trial in metastatic colorectal cancer.

Scott Kopetz, MD, PhD, FACP, discusses the rationale for the phase 3 BEACON CRC trial in BRAF V600E-mutant metastatic colorectal cancer.

Scott Kopetz, MD, PhD, FACP, discusses the safety data reported from the phase 3 BEACON CRC trial in BRAF V600E-mutant metastatic colorectal cancer.

Scott Kopetz, MD, PhD, FACP, discusses the updated survival data from the BEACON CRC study in BRAF V600E–mutated metastatic colorectal cancer.

Scott Kopetz, MD, PhD, FACP, discusses the rationale and primary endpoints of the BEACON CRC study in BRAF V600E–mutant metastatic colorectal cancer.

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the correlation between tumor sidedness and biomarkers in colorectal cancer.

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the biology of right- versus left-sided colorectal cancer.

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the significance of tumor sidedness in colorectal cancer.

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the rarity of fusions in patients with colorectal cancer (CRC).

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of molecular testing in colorectal cancer.

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses triplet therapy for patients with BRAF-mutant colorectal cancer